Objective:The study aim to construct patient-derived xenograft model of oral squamous cell carcinoma and to characterize whether it retained the clinicopathological features of the primary tumor.
Materials and methods:The patient-derived xenograft model of oral squamous cell carcinoma was constructed by inoculating the surgically excised oral squamous cell carcinoma tissue under the skin of immunodeficient mice with special treatment, and the P1-P3 generations were used for seeding and identification. The tumor tissues of patient-derived xenograft model were identified by both hematoxylin–eosin staining and immunohistochemistry to to determine the histomorphological consistency and molecular phenotypic similarity between the patient-derived xenograft model and the primary tumor tissues.
Results:Hematoxylin–eosin staining and immunohistochemical results showed that the pathological features and molecular phenotypic characteristics of the patient-derived xenograft model of oral squamous cell carcinoma were consistent with the primary tumor tissue.
Conclusion:In this study, patient-derived xenograft model of oral squamous cell carcinoma that retains the clinicopathological characteristics of the primary tumor tissue was successfully constructed and can be stably transmitted.
Clinical relevance:The patient-derived xenograft model of oral squamous cell carcinoma established in this study has significant implications for the study of oral squamous carcinoma, the personalized treatment of patients and the development of new anti-tumor drugs.
Oral squamous cell carcinoma is the most common malignancy of the head and neck with high morbidity and mortality. At present, platinum-based chemotherapy is the conventional chemotherapy regimen for patients with oral squamous cell carcinoma. However, due to the heterogeneity of tumors and individual differences of patients, chemotherapy regimens lacking individualized evaluation of tumor patients are often less effective. Therefore, personalized tumor chemotherapy is one of the effective methods for the treatment of malignant tumors in the future. Patient-derived xenograft model is a relatively new tumor xenograft model, which relies on immunodeficient mice to retain the characteristics of the primary tumor. Therefore, patient-derived xenograft model combined with drug screening technology to explore new tumor chemotherapy is the key research direction of future tumor treatment. In this study, patient-derived xenograft model of oral squamous cell carcinoma was successfully established, and it was verified by hematoxylin–eosin staining and immunohistochemistry that the constructed patient-derived xenograft model retained the pathological and molecular biological characteristics of primary tumors.